JP5123180B2 - 組織グリコーゲンの非侵襲性mri測定法 - Google Patents
組織グリコーゲンの非侵襲性mri測定法 Download PDFInfo
- Publication number
- JP5123180B2 JP5123180B2 JP2008522981A JP2008522981A JP5123180B2 JP 5123180 B2 JP5123180 B2 JP 5123180B2 JP 2008522981 A JP2008522981 A JP 2008522981A JP 2008522981 A JP2008522981 A JP 2008522981A JP 5123180 B2 JP5123180 B2 JP 5123180B2
- Authority
- JP
- Japan
- Prior art keywords
- magnetic resonance
- vivo
- glycogen
- proton
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920002527 Glycogen Polymers 0.000 title claims description 129
- 229940096919 glycogen Drugs 0.000 title claims description 129
- 238000000691 measurement method Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 86
- 239000008103 glucose Substances 0.000 claims description 71
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 70
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 38
- 238000001727 in vivo Methods 0.000 claims description 34
- 229920001282 polysaccharide Polymers 0.000 claims description 21
- 239000005017 polysaccharide Substances 0.000 claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 19
- 150000002772 monosaccharides Chemical class 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 238000002372 labelling Methods 0.000 claims description 8
- 238000001646 magnetic resonance method Methods 0.000 claims description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 7
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 7
- 239000002872 contrast media Substances 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 2
- 238000009738 saturating Methods 0.000 claims 3
- 238000009795 derivation Methods 0.000 claims 1
- 238000003384 imaging method Methods 0.000 description 35
- 235000012054 meals Nutrition 0.000 description 33
- 238000001514 detection method Methods 0.000 description 27
- 238000013507 mapping Methods 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 16
- 238000013459 approach Methods 0.000 description 16
- 238000001228 spectrum Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 6
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 210000000115 thoracic cavity Anatomy 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000005415 magnetization Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000009339 glycogen storage disease VII Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
- G01R33/485—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information [CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
Landscapes
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- General Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Optics & Photonics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Description
以下は、生物学的技術および医療技術に関する。ヒト組織におけるグリコーゲンのインビボで空間的に解像された検出、画像化、またはマッピングを例として参照して記載される。しかし、以下は、より一般には、種々の型の植物、動物、ヒト、または他の生物学的組織もしくはサンプルにおける内因性グリコーゲンもしくはグルコースの空間的に解像された検出、画像化、またはマッピングに関する。
electromagnetic)(TEM)コイルを備える。このコイル30は、単なる例である−他の実施形態では、別の型の高周波数コイル(例えば、表面コイル、局所用頭部コイル、局所用胴部コイル、表面コイルのアレイ、これらの種々の組み合わせなど)が含まれ得る。所定の高周波数コイルは、送信コイル、受信コイル、または送受信コイルであり得る。図1の図示される例示的装置において、上記高周波数コイル30は、送受信コイルであり、そして上記高周波数システムは、高周波数送信器32、高周波数受信器34、および送信モードと受信モードとの間を切り替えるための適切なスイッチング回路36をさらに備える。
Sasym(ω)=S(−ω)/S0−S(+ω)/S0 (1)
ここで式(1)において、S(+ω)は、+ωで飽和した後の水信号を示し、−ωは、+ωから反対側の水プロトン磁気共鳴周波数に対照的に位置した磁気共鳴周波数を示し、そしてS(−ω)は、−ωにおいて飽和した後の水信号を示す。この場合、+ωでのグリコーゲンもしくはグルコースのヒドロキシル基のプロトンの磁気共鳴周波数の存在は、非対称性を引き起こす。この分析アプローチは、造影剤で媒介される化学的交換飽和移動(CEST)において印加されるものと外見上は類似である。例えば、Wardら,A New Class of Contrast Agents for MRI Based
on Proton Chemical Exchange Dependent Saturation Transfer (CEST),J.Magn.Reson.vol.143,pages 79−87(2000);およびBalabanら,米国特許第6,963,769号を参照のこと。しかし、本実施形態において、式(1)は、ヒト身体または他のインビボ生物学的組織において内因性グリコーゲンもしくはグルコースの分析に関するのに対して、CEST検出は、被験体に投与される外因性造影剤の分析である。S(0)に関して参照することに加えて、S(−ω)に関して参照することも可能である。飽和は、高周波数照射の出力レベルに依存するので、この後者のアプローチは、あまり出力依存性でない非対称性を与える。
Claims (9)
- 磁気共鳴法であって:
選択された内因性の単糖もしくは多糖のヒドロキシル基の交換可能プロトンの磁気共鳴周波数において選択された改変を作り出す工程であって、該選択された改変が、インビボの被験体において該選択された内因性の単糖もしくは多糖のヒドロキシルプロトンを飽和させることもしくはヒドロキシルプロトンを非侵襲性磁気標識化することを含むインビボでの改変である、工程;
該インビボでの飽和または非侵襲性磁気標識化が実質的に有効である間に、立証的水プロトン磁気共鳴データをインビボで取得する工程;および
該立証的水プロトン磁気共鳴データに少なくとも基づいて、該選択された内因性の単糖もしくは多糖のインビボの濃度もしくは密度についての情報を導出する工程、
を包含する、方法。 - 請求項1に記載の磁気共鳴法であって:
水プロトンと、前記選択された内因性の単糖もしくは多糖のインビボで飽和または非侵襲性磁気標識化されたヒドロキシルプロトンとを交換することによる影響を実質的に受けていない参照水プロトン磁気共鳴データをインビボで取得する工程、
をさらに包含し、前記導出する工程は、前記立証的水プロトン磁気共鳴データと該参照水プロトン磁気共鳴データとを比較または組み合わせる工程を包含する、方法。 - 請求項1に記載の磁気共鳴法であって、前記選択された内因性の単糖もしくは多糖は、グルコースもしくはグリコーゲンであり、該磁気共鳴法が、前記被験体に外因性の造影剤を投与することを包含しない、磁気共鳴法。
- 前記立証的水プロトン磁気共鳴データをインビボで取得する工程は、立証的水プロトン磁気共鳴画像化データを取得する工程を包含し;そして
前記導出する工程は、該立証的水プロトン磁気共鳴画像化データから、内因性のグルコースもしくはグリコーゲンの空間分布を示すグルコースもしくはグリコーゲンの画像もしくはマップを導出する工程を包含する、
請求項3に記載の磁気共鳴法。 - 前記導出する工程は、前記選択された内因性の単糖もしくは多糖のヒドロキシル基の交換可能プロトンと、水のプロトンとの順方向交換速度(kexch)に少なくとも一部基づいて、該選択された内因性の単糖もしくは多糖のインビボ濃度または密度についての情報を計算することによって、インビボで取得された立証的水プロトン磁気共鳴データに対するpHの影響を測定する工程であって、該順方向交換速度(kexch)は、pHによって影響を受ける、工程をさらに包含する、請求項1に記載の磁気共鳴法。
- 前記選択された改変を作り出す工程は、複数の周波数のうちの各々において磁気共鳴をインビボで飽和させる工程であって、該複数の周波数は、該選択された内因性の単糖もしくは多糖のヒドロキシル基のプロトンの磁気共鳴周波数を含む工程を包含し、前記取得する工程は、各飽和操作後に立証的磁気共鳴データをインビボで取得する工程を包含する、請求項1に記載の磁気共鳴法。
- 磁気共鳴装置であって:
選択された内因性の単糖もしくは多糖のヒドロキシル基の交換可能プロトンの磁気共鳴周波数において選択された改変を作り出すための手段であって、該選択された改変が、インビボの被験体において該選択された内因性の単糖もしくは多糖のヒドロキシルプロトンを飽和させることもしくはヒドロキシルプロトンを非侵襲性磁気標識化することを含むインビボでの改変である、手段;
該インビボでの飽和または非侵襲性磁気標識化が実質的に有効である間に、立証的水プロトン磁気共鳴データをインビボで取得するための手段;および
該立証的水プロトン磁気共鳴データに少なくとも基づいて、該選択された内因性の単糖もしくは多糖のインビボの濃度もしくは密度についての情報を導出するための手段、
を備える、磁気共鳴装置。 - 請求項7に記載の磁気共鳴装置であって:
水プロトンと、前記選択された内因性の単糖もしくは多糖のインビボで飽和または非侵襲性磁気標識化されたヒドロキシルプロトンとを交換することによる影響を実質的に受けていない参照水プロトン磁気共鳴データをインビボで取得するための手段、
をさらに備え、前記導出は、前記立証的水プロトン磁気共鳴データと該参照水プロトン磁気共鳴データとを比較または組み合わせることを包含する、磁気共鳴装置。 - 請求項7に記載の磁気共鳴装置であって、前記選択された内因性の単糖もしくは多糖は、グルコースもしくはグリコーゲンであり、該磁気共鳴装置が、前記被験体に外因性の造影剤を投与するための手段を備えない、磁気共鳴装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70139005P | 2005-07-21 | 2005-07-21 | |
US60/701,390 | 2005-07-21 | ||
PCT/US2006/028314 WO2007014004A2 (en) | 2005-07-21 | 2006-07-21 | Non-invasive mri measurement of tissue glycogen |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009502244A JP2009502244A (ja) | 2009-01-29 |
JP2009502244A5 JP2009502244A5 (ja) | 2009-09-24 |
JP5123180B2 true JP5123180B2 (ja) | 2013-01-16 |
Family
ID=37308792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008522981A Expired - Fee Related JP5123180B2 (ja) | 2005-07-21 | 2006-07-21 | 組織グリコーゲンの非侵襲性mri測定法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7683617B2 (ja) |
EP (1) | EP1907873B1 (ja) |
JP (1) | JP5123180B2 (ja) |
CN (1) | CN101356447B (ja) |
WO (1) | WO2007014004A2 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2166368A1 (en) * | 2004-07-29 | 2010-03-24 | Otsuka Pharmaceutical Co., Ltd. | Nuclear magnetic resonance measuring method for solid samples |
US8536866B2 (en) | 2007-09-26 | 2013-09-17 | The Johns Hopkins University | Frequency referencing for chemical exchange saturation transfer (CEST) MRI |
WO2009089274A2 (en) * | 2008-01-07 | 2009-07-16 | New York University | Methods, system, and computer-accessible medium for assessment of glycosaminoglycan concentration in vivo by chemical exchange saturantion transfer |
US8278925B2 (en) * | 2008-03-26 | 2012-10-02 | The General Hospital Corporation | Method for relaxation-compensated fast multi-slice chemical exchange saturation transfer MRI |
US8611981B2 (en) | 2008-08-26 | 2013-12-17 | Bracco Imaging S.P.A. | MRI-CEST diagnostic technique based on non-punctual analysis |
WO2011091365A1 (en) * | 2010-01-25 | 2011-07-28 | Beth Israel Deaconess Medical Center | Method for measuring magnetization transfer between molecules with magnetic resonance imaging |
US8562529B2 (en) * | 2010-06-25 | 2013-10-22 | John C. Hill | Method and system for non-invasive determination of glycogen stores |
WO2012082874A2 (en) | 2010-12-14 | 2012-06-21 | The Johns Hopkins University | Use of non-labeled sugars and detection by mri for assessing tissue perfusion and metabolism |
US9372245B2 (en) * | 2011-11-21 | 2016-06-21 | The Trustees Of The University Of Pennsylvania | Endogenous magnetization contrast in MRI |
WO2013082137A1 (en) * | 2011-11-28 | 2013-06-06 | New York University | Apparatus, system, method and computer-readable medium for isolating chemical exchange saturation transfer contrast from magnetization transfer asymmetry under two-frequency rf irradiation |
DE102013208475B4 (de) * | 2013-05-08 | 2014-11-27 | Siemens Aktiengesellschaft | HF-Anregung mit zwei Resonanzfrequenzen zum Nachweis des CEST-Effekts mittels einer Magnetresonanzanlage |
US9638781B2 (en) * | 2014-02-03 | 2017-05-02 | Toshiba Medical Systems Corporation | Enhancement of MT effect and/or CEST effect |
US10613180B2 (en) | 2014-03-06 | 2020-04-07 | The Johns Hopkins University | Methods and systems of assessing tissue vascular permeability using non-labeled dextran |
US10203389B2 (en) | 2014-04-23 | 2019-02-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method and system for monitoring glucose transport and metabolism by spin-lock magnetic resonance |
US9642593B2 (en) | 2014-09-19 | 2017-05-09 | MuscleSound, LLC | System and method for non-invasive determination of human body fat |
US10267881B2 (en) | 2014-12-18 | 2019-04-23 | The Johns Hopkins University | Multi-echo parametric variation saturation (MePaVARS CEST imaging and other MR imaging |
GB2552611B (en) * | 2015-02-23 | 2021-10-13 | Synaptive Medical Inc | System and method for delta relaxation enhanced magnetic resonance imaging |
US11013490B2 (en) | 2016-11-15 | 2021-05-25 | Musclesound, Inc. | Non-invasive determination of muscle tissue size |
US11064971B2 (en) | 2016-11-30 | 2021-07-20 | Musclesound, Inc. | Non-Invasive determination of muscle tissue quality and intramuscular fat |
US11096658B2 (en) | 2017-02-02 | 2021-08-24 | Musclesound, Inc. | Non-invasive determination of pennation angle and/or fascicle length |
US11160493B2 (en) | 2017-03-03 | 2021-11-02 | Musclesound, Inc. | System and method for determining a subject's muscle fuel level, muscle fuel rating, and muscle energy status |
JP6885207B2 (ja) * | 2017-06-14 | 2021-06-09 | 愛知製鋼株式会社 | マーカ検出方法及び車両用システム |
US10775462B2 (en) * | 2017-07-05 | 2020-09-15 | The General Hospital Corporation | System and method for direct saturation-corrected chemical exchange saturation transfer (DISC-CEST) |
JP2022500656A (ja) * | 2018-09-14 | 2022-01-04 | 10250929 カナダ インコーポレーテッド | 代謝産物レベルのin−vivo非侵襲的測定のための方法及びシステム |
WO2021072730A1 (zh) * | 2019-10-18 | 2021-04-22 | 深圳先进技术研究院 | 一种灌注成像方法及装置 |
US20230408611A1 (en) * | 2020-11-24 | 2023-12-21 | The Johns Hopkins University | Magnetic resonance imaging of glycogen and other polysaccharides by magnetic coupling with water |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2698177B1 (fr) * | 1992-11-13 | 1994-12-30 | Sadis Bruker Spectrospin | Procédé d'excitation et d'acquisition de signaux de résonance magnétique nucléaire, notamment dans l'eau légère. |
US5639906A (en) * | 1994-10-11 | 1997-06-17 | The United States Of America As Represented By The Department Of Health And Human Services | Fluorescent and NMR sensitive pH indicators |
ES2123449B1 (es) * | 1997-03-06 | 1999-09-16 | Univ Madrid Nac Educacion | Procedimiento para la obtencion de imagenes y espectros del ph extracelular por resonancia magnetica con indicadores extrinsecos conteniendo 1h o 19f. |
EP1178837A2 (en) | 1999-04-21 | 2002-02-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method for enhancing contrast produced by mri |
ITMI20011706A1 (it) * | 2001-08-03 | 2003-02-03 | Bracco Imaging Spa | Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic |
US20040030239A1 (en) | 2001-12-13 | 2004-02-12 | The Johns Hopkins University School Of Medicine | Method for MR/NMR imaging |
EP1466629A1 (en) * | 2003-04-11 | 2004-10-13 | BRACCO IMAGING S.p.A. | Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "CEST" applications |
US7253620B1 (en) * | 2004-03-08 | 2007-08-07 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Spectrally selective suppression with steady-state free precession |
-
2006
- 2006-07-21 EP EP06788066.6A patent/EP1907873B1/en not_active Not-in-force
- 2006-07-21 WO PCT/US2006/028314 patent/WO2007014004A2/en active Application Filing
- 2006-07-21 JP JP2008522981A patent/JP5123180B2/ja not_active Expired - Fee Related
- 2006-07-21 US US11/996,162 patent/US7683617B2/en active Active
- 2006-07-21 CN CN2006800347307A patent/CN101356447B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2007014004A2 (en) | 2007-02-01 |
US7683617B2 (en) | 2010-03-23 |
US20080197840A1 (en) | 2008-08-21 |
JP2009502244A (ja) | 2009-01-29 |
EP1907873A2 (en) | 2008-04-09 |
CN101356447A (zh) | 2009-01-28 |
WO2007014004A3 (en) | 2008-04-10 |
EP1907873B1 (en) | 2015-02-25 |
CN101356447B (zh) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5123180B2 (ja) | 組織グリコーゲンの非侵襲性mri測定法 | |
JP2009502244A5 (ja) | ||
Zhu et al. | In vivo 17O NMR approaches for brain study at high field | |
US4585992A (en) | NMR imaging methods | |
Barfuss et al. | Whole-body MR imaging and spectroscopy with a 4-T system. | |
Kan et al. | In vivo 31P MRS detection of an alkaline inorganic phosphate pool with short T1 in human resting skeletal muscle | |
Platt et al. | 7 Tesla and beyond: advanced methods and clinical applications in magnetic resonance imaging | |
Kiliçkesmez et al. | Non-breath-hold high b-value diffusion-weighted MRI with parallel imaging technique: apparent diffusion coefficient determination in normal abdominal organs | |
Löffler et al. | Localized spectroscopy from anatomically matched compartments: improved sensitivity and localization for Cardiac31P MRS in humans | |
US8513945B2 (en) | System, method and computer-accessible medium for providing breath-hold multi-echo fast spin-echo pulse sequence for accurate R2 measurement | |
Rodgers et al. | Cardiovascular magnetic resonance: physics and terminology | |
Chowdhury et al. | Quantification of prostate cancer metabolism using 3D multiecho bSSFP and hyperpolarized [1‐13C] pyruvate: metabolism differs between tumors of the same Gleason grade | |
Ma et al. | Cardiac measurement of hyperpolarized 13C metabolites using metabolite‐selective multi‐echo spiral imaging | |
Dietrich et al. | Fast oxygen‐enhanced multislice imaging of the lung using parallel acquisition techniques | |
Zhang et al. | Navigator‐based slice tracking for kidney pCASL using spin‐echo EPI acquisition | |
Nakae et al. | Assessment of myocardial creatine concentration in dysfunctional human heart by proton magnetic resonance spectroscopy | |
JP2002209868A (ja) | 原子核スピン緩和及び分子拡散の促進方法並びに磁気共鳴撮像装置 | |
BRADBURY et al. | Nuclear magnetic resonance techniques in medicine | |
Wang et al. | Overview and progress of X-nuclei magnetic resonance imaging in biomedical studies | |
US9075122B2 (en) | Method, system and computer-accessible medium for providing multiple-quantum-filtered imaging | |
Cutillo et al. | Determination of lung water content and distribution by nuclear magnetic resonance imaging | |
Stabinska et al. | Two point Dixon-based chemical exchange saturation transfer (CEST) MRI in renal transplant patients on 3 T | |
US11389106B2 (en) | Non-invasive diagnostic biomarker for pancreatic islet populations | |
Chernoff et al. | Principles of magnetic resonance imaging | |
Boada et al. | Non-invasive assessment of tumor proliferation using triple quantum filtered/sup 23/Na MRI: technical challenges and solutions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090508 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100422 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120927 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121025 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151102 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |